Skip to content

Suture Length Effects in Acupoint Implantation for Abdominal Obesity

Effects of Different Lengths of Surgical Sutures in Acupoint Catgut Implantation on Simple Abdominal Obesity in Adults

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07125716
Enrollment
78
Registered
2025-08-15
Start date
2025-08-01
Completion date
2026-07-31
Last updated
2025-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Obesity, Obesity

Brief summary

Obesity is a metabolic disorder and has become a global health issue with a steadily increasing prevalence. According to the Health Promotion Administration's statistical report, the overweight and obesity rate among adults in Taiwan was 50.3% between 2017 and 2020. Based on the Ministry of Health and Welfare's criteria, a BMI ≥27 kg/m² is classified as obese. Studies have shown that acupuncture can effectively reduce body weight with low cost and minimal side effects. Acupoint catgut embedding is a treatment method that combines traditional meridian acupuncture with modern medical materials by implanting surgical sutures into acupoints to provide continuous stimulation. A 2022 systematic review found that catgut embedding is more effective than traditional acupuncture, requires fewer treatment sessions, and has a high safety profile. However, no studies have yet investigated whether different lengths of implanted surgical sutures affect treatment outcomes. This study is a single-center, double-blind, randomized controlled trial aimed at identifying the optimal suture length for acupoint catgut embedding, in order to enhance its efficiency and therapeutic effect.

Interventions

DEVICE1 inch

1 inch suture length

DEVICE0.5 inch

0.5 inch suture length

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Willing to sign a written informed consent form 2. BMI ≥27 kg/m² (Ministry of Health and Welfare standard) 3. Waist circumference ≥90 cm for men 4. Waist circumference ≥80 cm for women 5. Age between 18 and 65 years

Exclusion criteria

1. Endocrine disorders (thyroid disease, pituitary disorders, and diabetes) 2. Autoimmune diseases (systemic lupus erythematosus, Sjögren's syndrome, and rheumatoid arthritis) 3. Heart diseases (heart failure, arrhythmia, etc.) 4. Abnormal liver function 5. Abnormal kidney function 6. Stroke within the past year 7. Pregnant or breastfeeding women 8. Coagulation disorders 9. Tumors 10. Participation in weight loss treatment within the past 6 months 11. Any other condition deemed unsuitable for the trial by the physician

Design outcomes

Primary

MeasureTime frame
Waist circumference1 week,4 week,8 week

Secondary

MeasureTime frame
hip circumference1 week,4 week,8 week
weight1 week,4 week,8 week
BMI1 week,4 week,8 week
VAS1 week,4 week,8 week
Ultrasound Fat Thickness1 week,4 week,8 week

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026